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INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) which encompasses 
both chronic bronchitis and emphysema is one of the commonest respiratory 
condition of adults in the developing world.  
In the western world, COPD is probably the fourth commonest cause of 
death in middle aged to elderly men. According to estimates, COPD would 
become the third biggest cause of death in the world by 2020.  
Going by the available Indian data for 1996, there were 12.3 million 
cases of COPD in our country. COPD poses an enormous burden to our 
society, both in terms of direct cost to health care services and indirect cost to 
society in terms of loss of production. 
Despite the high prevalence and enormous cost to health care and 
society, COPD has received little attention in respect to other respiratory 
conditions like Asthma and Lung Cancer. 
This is likely to be because COPD is thought of as a self inflicted 
disease with few effective treatments and mainly affects a more elderly which 
has less vocal population, which is not true. 
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REVIEW OF LITERATURE 
HISTORICAL PERSPECTIVE 
The beginning of modern chest medicine can be traced to the classic 
volume by Laennec, “A treatise on diseases of the chest” which appeared in 
1821 laid the corner stone of modern chest medicine. 
In his treatise, Laennec, devoted one chapter to “Pulmonary Catarrh or 
Bronchitis” and emphysema. The chapter on bronchitis distinguishes between 
acute and chronic form and sub divides chronic bronchitis into two types – the 
humid (Copious Expectoration) and dry (Scarcely any Expectoration). He 
identified “Dilatation of air cells” as the essential feature of emphysema. 
Recognition of chronic bronchitis as a potentially grave illness rather 
than as a trivial but not disabling disease had to wait the “London Fog” of 
1953, which was brought about by bad weather and air pollutants, carried with 
it a surge in morbidity and mortality due to chronic lung disease. 
After World War II, clinical investigations of pulmonary disease were 
provided with a new diagnostic armamentarium; Pulmonary Function tests 
were extended beyond simple spirometry and innovative techniques were 
developed for assessing the distribution of gases within the lungs which greatly 
improved our understanding of COPD. 
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DEFINITION 
The Global Initiative on Obstructive Lung Disease (GOLD) has 
proposed a definition of COPD that is based on evidence of air flow 
obstruction. Accordingly it is defined as a “disease state characterized by air 
flow limitation that is not fully reversible. The air flow limitation is usually 
both progressive and associated with an abnormal inflammatory response of the  
lungs to noxious particles or gases”. 
1. Chronic Bronchitis 
It is defined as persistence of cough and excessive mucous secretion on 
most days over a three month period for at least two successive years.  
2. Emphysema 
It is defined as abnormal permanent enlargement of the gas exchanging 
unit of lungs in association with destruction of alveolar walls and without 
obvious fibrosis. 
Burden of COPD   
Epidemiology 
Most of the information available on COPD prevalence, morbidity and 
mortality comes from developed countries. Even in these countries, accurate 
epidemiological data on COPD are difficult and expensive to collect.  
Prevalence and morbidity data greatly underestimate the total burden of 
COPD because the disease is usually not diagnosed until it is clinically 
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apparent and moderately advanced. The imprecise and variable definitions have 
made it hard to quantify the morbidity and mortality of this disease in 
developed and developing countries. 
Prevalence 
In the “Global burden of disease” study conducted by World Health 
Organization (WHO) the world wide prevalence of COPD in 2002 was 
estimated to be 11.6 / 1000 in men and 8.77 / 1000 in women. The prevalence 
is highest in countries where cigarette smoking has been, or still is very 
common. 
Globally, the study showed COPD results in 2.75 million deaths overall 
representing 4.8 % of all deaths.  
Now COPD is the fourth leading cause of death worldwide and by the 
year 2020 it will be the third leading cause of death and fifth leading cause of 
DALY’s lost worldwide (Disability Adjusted Life Years). 
Pathogenesis 
COPD is characterized by chronic inflammation through out the 
airways, parenchyma and pulmonary vasculature. Macrophages , T 
lymphocytes (Predominantly CD 8 + ) and neutrophils are increased in various 
parts of the lung. Activated inflammatory cells release a variety of mediators 
including leukotriene B4, interleukin 8, tumor necrosis factor (TNF) and others 
capable of damaging lung structures and / or sustaining neutrophilic 
inflammation. 
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In addition to inflammation, two other processes thought to be important in 
the pathogenesis of COPD are: 
(i) imbalance of proteinases and anti proteinases in the lung  
(ii) oxidative stress 
Pathology 
Pathological changes characteristic of COPD are found in the central 
airways, peripheral airways, lung parenchyma and pulmonary vasculature. 
Central airways (> 2-4 mm in internal diameter) 
Enlarged mucus secreting glands  
Increase in the number of goblet cells  
Peripheral airways (< 2 mm in internal diameter) 
Structural remodeling of the airway wall, with increasing collagen 
content and scar tissue formation that narrows the lumen and produces fixed 
airway obstruction. 
Lung parenchyma 
Centri lobular emphysema is predominantly seen in these patients 
because it is the most frequent type of emphysema seen in smokers. Recent 
studies indicate increased collagen per unit volume of air space wall in 
emphysematous lung from smokers. 
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Pulmonary vasculature 
There will be thickening of the intima initially followed by smooth 
muscle hyperplasia as the disease progresses. 
Pathophysiology 
Pathological changes in the lungs lead to corresponding physiological 
changes characteristic of the disease which occur in the following order: 
Mucus hypersecretion 
Ciliary dysfunction 
Airflow limitation 
Pulmonary hyperinflation 
Gas exchange abnormalities 
Pulmonary hypertension 
Cor pulmonale 
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Clinical hallmarks 
Table - 1 
 Predominant bronchitis  Predominanat 
emphysema 
General 
appearance 
Mesomorphic; overweight, 
dusky with suffused 
conjunctivae, warm 
extremities 
Thin, often emaciated, 
pursed lip breathing, 
anxious, normal or cool 
extremities 
Age, years 40 to 55 years 50 to 75 years 
Onset Cough Dyspnea 
Cyanosis Marked  Slight to none 
Cough More evident than dyspnea  
Sputum Copious Scanty 
Upper respiratory 
infections 
Common Occasional 
Breath sounds Moderately diminished Markedly diminished 
Corpulmonale 
and right sided 
heart failure 
Common Only during bouts of 
respiratory infection and 
terminal 
Other names Blue bloater Pink puffer 
 
Pink puffer 
Complains of severe dyspnea but has a relatively good blood oxygen 
level and does not have hypercapnia. Such patients tend to be thin and does not 
have corpulmonale or right sided heart failure.  
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Blue bloater 
He has peripheral edema caused by right heart failure and has more 
severe hypoxemia and hypercapnia and less dyspnea. 
Cardio vascular manifestations 
COPD is associated with several complications, the most serious of 
which are Pulmonary arterial hypertension, right ventricular hypertrophy 
(Corpulmonary) and right ventricular failure. 
Chronic corpulmonary is defined as “ hypertrophy of the right ventricle 
resulting from the disease affecting the function and / or structure of the lung, 
except when these pulmonary alterations are the result of diseases that 
primarily affect the left side of the heart or congenital heart disease”.  
Pathophysiology of pulmonary hypertension 
Pulmonary hypertension in COPD is due to multiple factors.: 
(i) Pulmonary vasoconstriction caused by alveolar hypoxia, academia 
and hypercarbia  
(ii) Compression of pulmonary vessels by the high lung volume  
(iii) Loss of small vessels in the vascular bed in regions of emphysema 
and lung destruction 
(iv) Increased cardiac output and blood viscoscity from polycythemia 
secondary to hypoxia 
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Of these, hypoxia is the most important factor and is associated with 
pathological changes that occur characteristically in the peripheral pulmonary 
arterial bed.  
Intimal thickening appears to be a early event that occurs in association 
with progressive airflow limitation. The structural rather than hypoxic 
vasoconstriction is required for the development of sustained pulmonary 
hypertension in patients with COPD. 
With mild to moderate grades of COPD, (FEV1 40% to 80% of 
predicted), pulmonary artery pressure (Ppa) is usually normal at rest, but 
increases with moderate exercise or exposure to cold. In the presence of severe 
COPD (FEV1 < 40% of predicted), hypertension is usually present at rest 
(Mean Ppa > 20 mm Hg) and pulmonary arterial pressure undergoes a 
disproportionate increase with mild exercise. 
Ppa can increase acutely during episodes of hypoxia that occur during 
sleep and it has been suggested that recurrent nocturnal pulmonary 
hypertension can eventually lead to “fixed” hypertension as a result of 
structural changes in the arterial wall. 
Pulmonary hypertension in COPD progresses over time and its severity 
correlates with the degree of airflow obstruction and impairment of pulmonary 
gas exchange. 
Weitzenblum  et al   studied the evolution of Ppa in a group of 93 
patients with COPD for 5 years. They found that Ppa increased at an average 
rate of  0.08 kPa (0.6mm Hg) per year. The rate of increase of Ppa was slightly 
higher in patients who did not have pulmonary hypertension at the beginning of 
the study compared with those who already had pulmonary hypertension. 
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An intriguing question is when pulmonary hypertension commences in 
the natural history of COPD. In a recent study, Kessler et al assessed the 
evolution of pulmonary hemodynamics in a group of 131 patients with 
moderate COPD who did not have pulmonary hypertension at rest, although 
58% developed pulmonary hypertension during exercise.  
The results of the study indicates that in COPD, changes in pulmonary 
circulation may start several years before pulmonary hypertension is apparent 
at rest and that exercise testing might be useful in showing abnormalities of the 
pulmonary circulation. 
Although left ventricular function is normal in  most patients who have 
COPD, it may deteriorate when corpulmonale and right ventricular failure 
develop because of right ventricular dilatation, septal shift and left ventricular 
compliance. 
Chronic corpulmonale is associated with a high incidence of cardiac 
arrhythmias, particulary supra ventricular arrhythmias. 
ELECTRO CARDIOGRAPHIC MANIFESTATIONS 
Chronic obstructive airways disease influence the electrical events of the 
heart in the following basic respects: 
1. the voluminous lungs have an insulating effect and thereby diminish the 
transmission of electrical potential to the registering electrodes 
2. the heart descends to a lower position within the thorax due to a 
lowering of the diaphragm. This will alter the position of the heart 
relative to conventional precordial electrode postions. 
 11
3. the right ventricle and right atrium become compromised due to a 
reduction of the pulmonary vascular bed. This will result in right 
ventricular hypertrophy as well as right atrial enlargement. 
Decreased magnitude of the electrocardiographic deflexions 
The voluminous lungs impair electrical transmission. The QRS and T 
deflexions are therefore markedly diminished in magnitude. 
Lead I sign   
In patients with COPD the frontal plane P, QRS and T wave axes are not 
infrequently all directed at around + 90 degree which are either precisely or 
almost perpendicular to the standard lead I axis. As a result of this Lead I 
reflects absent or very low amplitude P, QRS and T wave complexes giving the 
appearance of minimally disturbed base line. This ECG phenomenon is known 
as the Lead I sign. 
Right atrial enlargement 
The frontal plane P wave axis is directed to the right of +60 degree. It is 
commonly and in a way characteristically directed to + 90 degree  
P pulmonale 
It is reflected by P waves which are tall and peaked in standard leads II, 
III aVF, and is the expression of right atrial enlargement. 
 12
The combination of right axis deviation and tall peaked P waves is 
called P pulmonale. A comparison of interstitial pulmonary fibrosis and COPD 
showed that a deviation of the frontal plane P wave axis to the right of +70 
degree only occurs with COPD. 
Abnormalities of the QRS complex 
Right QRS axis deviation 
The frontal plane QRS axis is deviated to the right and commonly 
directed to +90 degree. When it is deviated further, the frontal plane leads will 
usually reflect an S1Q3R3 pattern. In very severe cases it may be directed to 
the “northwest” region. 
Left QRS axis deviation 
This occurs in about 10% of cases. The mechanism is still speculative.  
S1, SII, SIII syndrome 
Prominent terminal S waves may appear in standard leads I and II or in 
I, II and III giving rise to the SI, S II, S III syndrome. This indirectly reflects 
posterior displacement of the apex.  
Posterior displacement of the mean QRS axis 
The mean QRS axis may also be displaced somewhat posteriorly so that 
it tends to be more obliquely oriented to the horizontal plane.  
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Abnormalities of the precordial QRS form 
There is diminution of QRS magnitude in all the leads. It is not 
uncommon for all the precordial leads to reflect rS complexes. In very severe 
cases the R : S ratio is usually less than 1 in leads V4 to V6, and R wave 
amplitude in lead V6 may be less than 5 mm. The transition zone is frequently 
displaced to V6 or even further to the left.  
Right bundle branch block 
There may occasionally be transient complete or incomplete RBBB with 
an exacerbation of the emphysema and increase in oxygen desaturation. 
Right ventricle hypertrophy is mainly reflected by: 
a. right axis deviation 
b. prominent terminal S waves in the left precordial leads 
The single most characteristic ECG feature of diagnosis in COPD is said 
to be P wave axis of +70 to +90 degrees. 
Abnormalities of T waves 
Frontal T wave axis 
It is usually similar in direction to that of QRS axis. The T wave is 
diminished in amplitude in all leads. The T wave may be inverted in the right 
precordial leads especially when pulmonary hypertension is marked. 
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Exacerbation of the disease with an increase in oxygen desaturation may 
be associated with elevation of ST segment in leads II, III and AVF. This 
manifestation is reversible. 
ECHOCARDIOGRAPHY 
Echocardiography is nearly twice as sensitive as clinical examination in 
detecting corpulmonale. However it may be suboptimal in persons with hyper 
inflation because of poor transmission of sound waves by the increased 
retrosternal air space.  
Systolic pulmonary artery pressure can be estimated with pulsed 
Doppler by determining the blood flow velocity in the main pulmonary artery 
or in the regurgitant jet from the tricuspid valve. The tricuspid valve regurgitant 
jet can be used to determine the right ventricular – atrial gradient using the 
modified Bernoulli’s equation 
P = 4 V2 
Where P = peak pressure difference between the right ventricle (RV) 
and the right atrium (RA) 
V = peak velocity of tricuspid regurgitant jet  
This pressure is then added to the mean right atrial pressure to obtain the 
systolic Ppa. 
Sensitivity, specificity and positive and negative predictive values of 
systolic pulmonary artery pressure estimation for diagnosis of pulmonary 
hypertension were 85, 55, 52 and 87% respectively. 
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M Mode, 2D – Echo and Color Doppler features of patients with PAH 
Table 2 
Variables Right heart Left heart 
M - mode   
Diminished or absent atrial wave of the pulmonary valve  
 
2 D 
Echo 
  
 RV hypertrophy, RV Dilatation Reduced LV end diastolic 
volume 
 RV abnormal systolic function Reduced LV end systolic 
volume 
 RV pressure overload pattern of 
IVS 
LV ejection fraction within  
normal limits 
 Right atrial dilatation  Increased IVS thickness 
 Dilated pulmonary artery  IVS / posterior wall thickness 
ratio more than 1 
 Inter atrial septum bows right to 
left 
 
 
Color 
Doppler 
  
 Tricuspid regurgitation  
 Pulmonary insufficiency  
 Elevated pulmonary artery systolic pressure E/A ratio < 1 
 RV outflow tract acceleration time < 0.1 seconds  
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E/A Ratio 
Ratio between early peak transmitral flow velocity and late peak systolic 
velocity 
RV – right ventricle 
LV – left ventricle 
IVS – inter ventricular septum 
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AIMS AND OBJECTIVES 
To study the electrocardiographic and echocardiographic changes in 
chronic obstructive pulmonary disease. 
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MATERIALS AND METHODS 
SETTING  
 The study was conducted in Government General Hospital, Chennai.  
DESIGN OF STUDY 
It was an observational type of study. Interview technique was used to 
collect information on a predesigned proforma. 
PERIOD OF STUDY  
It was conducted in a time period from June 2005 to June 2006. 
SAMPLE SIZE 
Fifty cases of COPD. 
SELECTION OF STUDY SUBJECTS 
COPD patients above 30 years of age, attending the outpatient clinic in 
the admission day of my unit and who were admitted in my ward in 
Government General Hospital, Chennai were selected for this study. 
INCLUSION CRITERIA 
 All COPD patients above 30 years of age, diagnosed clinically 
and satisfying the spirometric criteria were included in the study. 
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 A diagnosis of COPD should be considered in any patient who 
has symptoms of 
i. Chronic cough  
- Present intermittently or everyday  
- Often present throughout the day 
- Seldom only nocturnal  
ii. Chronic sputum production  
 - Any pattern of Chronic sputum production may indicate COPD 
iii. Dyspnea that is  
- Progressive (worsens over time) 
- Persistent (present everyday) 
- Worse on exercise 
- Worsens during respiratory infections 
iv. History of exposure to risk factors 
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RISK FACTORS 
Table 3 
Environmental Host -Related 
Indoor air pollution from biomass 
fuel use in setting of inadequate 
ventilation  
Airway hyper responsiveness  
Occupational dusts and chemicals  Severe hereditary alpha1antitrypsin 
deficiency. 
History of severe childhood 
respiratory infections  
Low birth weight  
Outdoor air pollution  Maternal cigarette smoking during 
gestation 
Low socio economic status  
Intra venous drug use (Methyl 
Phenidate, Methadone, Talc 
granulomatosis) 
 
 
 Of these, cigarette smoking is overwhelmingly the most important risk 
factor in the development of COPD. 
Spirometric criteria 
 The diagnosis is confirmed by spirometry. The presence of a post 
bronchodilator FEV 1 < 80% of the predicted value in combination with an 
FEV 1 / FVC < 70% confirms the presence of air flow limitation that is not 
fully reversible. 
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Exclusion criteria 
Patients with other respiratory diseases like: 
Asthma  
Tuberculosis 
Bronchiectasis 
Lung malignancy were excluded from the study. 
Patients with: 
Valvular heart diseases  
Coronary heart diseases 
Systemic hypertension 
Cardio myopathies 
AIDS were excluded. 
All patients were subjected to: 
- Routine blood investigations 
- Urine analysis 
- Sputum analysis for AFB stain, gram stain, culture and sensitivity 
was done. 
- Mantoux test was done 
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- ELISA for HIV 
- Arterial blood gas analysis 
- Chest X-ray PA views and lateral views were taken for all 
patients 
- Electrocardiograph was taken 
- All patients were subjected to both 2 D and Doppler 
Echocardiogram and pulmonary artery pressure measured. 
- Pulmonary function test was done using spirometry  
SPIROMETRY 
 Several tests are used to study various aspects of pulmonary functions. 
Amongst these spirometry is the most basic and useful method for evaluating 
pulmonary function.  
Spirometry is a simple expression of a complex process, just like blood 
pressure. It measures air flow from fully inflated lungs over time in litres. Thus 
the forced vital capacity (FVC) is the amount of air exhaled from fully inflated 
lungs and FEV 1 measures the air flow during the first part of vital capacity 
manoeuvre.  
Selecting a Spirometer 
 The American Thoracic Society (ATS) recommends that the equipment 
should be such that: 
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- it can be calibrated with a three litre syringe  
- it should record atleast FVC and FEV1 
- it should record a flow volume curve or a flow volume loop or both (if 
possible) 
Contra indications for performing Spirometry 
It is recommended that patients should not be tested within one month of 
myocardial infarction. 
Patients with any of the conditions listed below are unlikely to achieve 
optimal or reproducible results. 
- Chest or abdominal pain of any cause 
- Oral or facial pain exacerbated by a mouth piece 
- Stress incontinence 
- Dementia or confused state 
Performing Spirometry 
According to the current ATS statement, spirometry may be performed 
either in the sitting or standing position. The sitting position is considered safe 
in order to prevent falling due to syncope. However, in obese subjects, the 
standing position may be preferred.  
- Smoking within one hour of testing 
- Consuming alcohol within four hours of testing 
- Performing vigorous exercise within thirty minutes of testing 
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- Wearing clothing that substantially restricts full chest and abdominal 
expansion 
- Eating a large meal within two hours of testing 
If it is performed to diagnose airway disorder, avoid: 
- Short acting bronchodilators within previous six hours 
- Long acting bronchodilators within previous twelve hours 
- Slow release theophyllines within the previous twenty four hours 
Spirometric manoeuvre 
The procedure must be instructed and demonstrated to the patient. The 
patient then performs spirometry in the following steps: 
Expiratory manoeuvre 
1. Take a full deep breath away from the spirometer 
2. Hold the mouth piece between the lips to create a good seal 
3. Expire as fast and as hard as possible for as long as possible until no 
breath is left 
Expiratory and inspiratory manoeuvre 
1. Hold the mouth piece between the lips to create a good seal 
2. Breathe in and out for two to three tidal breaths 
3. Expire as fast and as hard as possible for as long as possible until no 
breath is left 
4. Inspire rapidly to maximum capacity 
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 Spirometry should be recorded fifteen to thirty minutes after 
administration of a short acting beta-agonist eg. 200 to 400 microgram of 
salbutamol to check for bronchodilator reversibility.  
Acceptable tests 
- The effort should be maximal, smooth and cough free 
- Exhalation time should be atleast six seconds 
- End of test is indicated by a two second volume plateau 
- Reproducibility as indicated by FVC should be within 5% or 100 ml 
between the highest and next best among three acceptable tests 
- If three reproducible tests are not available, upto 8 manoeuvres should 
be attempted 
- The best values of three acceptable tests are used for interpretation 
- If after 8 manoeuvres, 3 reproducible tests are not available, then the test 
with highest values may be used. 
Reversibility testing 
Broncho dilator reversibility 
 Spirometry is recorded fifteen to thirty minutes after administration of 
short acting beta agonist eg. 200 to 400 mcg of salbutamol is used. 
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Calculation of % improvement 
FEV1 (post broncho dilator) – FEV1 (base line) 
        x  100 
FEV1 (base line) 
 Good bronchodilator reversibility is indicated by improvement in FEV1 
by 200 ml     and > 12%.  
Spirometry in COPD 
Gold standard for confirmation of COPD 
- Decreased FEV1 with concomitant reduction in FEV1 / FVC ratio with 
a poor or absent broncho dilator reversibility and normal or reduced 
FVC 
- FEV1 / FVC % < 70 is used to diagnose COPD 
For assessment of Severity of COPD by FEV1% 
Severity of COPD (GOLD classification) 
Table 4 
0 At risk Spirometry normal but symptoms evident 
I Mild FEV1 / FVC % < 70 FEV1 > 80% predicted 
II Moderate FEV1 / FVC % < 70 FEV1 50 to 80% predicted 
III Severe FEV1 / FVC % < 70 FEV1 30 to 50% predicted 
IV Very 
severe 
FEV1 / FVC % < 70 FEV1 < 30% predicted (or) 
FEV1 < 50% predicted with 
chronic respiratory failure  
 
 27
PROFORMA 
Name:     Age:   Sex: 
Height (metres):   Weight (Kgs): 
Occupation:    Income: 
Presenting complaints 
Cough with expectoration 
Dyspnea 
Wheeze 
Cyanosis 
Puffiness of face 
Reduced urine output 
Swelling of legs 
Chest pain 
Palpitation 
Past history 
Tuberculosis 
Systemic hypertension 
Diabetes mellitus 
Asthma 
Ischemic heart disease 
Previous hospitalization for similar complaints 
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Personal history 
Diet  veg or Non-Veg 
Smoking–cigarettes or beedis  - number of packs per day and duration of 
smoking 
Chewing pan 
Alcohol intake 
Occupational history 
Investigation 
Blood hemogram 
Blood sugar 
Blood urea 
Serum creatinine 
Lipid profile 
Sputum 
Gram stain 
AFB stain 
Culture and sensitivity 
Mantoux test  
ELISA for HIV 
Urine  
Albumin 
Sugar 
Deposits 
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Chest X-ray 
PA view 
Lateral view 
ECG in all leads 
Arterial blood gas (ABG) analysis 
Echo cardiography 
Pulmonary function test 
Percentage predicted 
FEV1 
FVC 
FEV1 / FVC % 
PEFR 
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OBSERVATION 
AGE – DISTRIBUTION 
Table 5 
S. 
No. 
Age 
(years) 
Predominant 
bronchitis 
Predominant 
emphysema 
Total percentage
1. 30- 39 2 - 2 4 
2. 40 - 49 10 2 12 24 
3. 50 – 59 16 6 22 44 
4. 60 & above 7 7 14 28 
 
Lower age limit of 30 years was selected because this was the most 
frequently available cut off age in the reported studies. More over COPD is rare 
below this age. 
In my study, it is seen predominantly in persons over 40 years of age 
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SEX DISTRIBUTION 
Table 6 
S. No Sex Predominant 
bronchitis 
Predominant 
emphysema 
Total Percentage 
1. Male 
 
23 11 34 68 
2. Female 
 
12 4 16 32 
 
The male female ratio is 2.12:1. 
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SMOKING PATTERN 
Table 7 
S. 
No 
Pack years Predominant 
bronchitis 
Predominant 
emphysema 
Total Percentage 
1. > 30 12 6 18 36 
2. 20 – 30 8 3 11 22 
3. < 20 3 1 4 8 
4. Non smoker 12 5 17 34 
  
Pack year  
It is calculated by multiplying the number of packs of cigarettes smoked 
per day by the number of years the person has smoked. 
Commonly seen in persons with a smoking pattern of more than 20 pack 
years. 
33 of the 34 non smokers in this study were females. 
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PULMONARY FUNCTION TEST 
SPIROMETRY 
Table 8 
S. No FEV1 / 
FVC % 
Predominant 
bronchitis 
Predominant 
emphysema 
Total Percentage 
1. 30 – 40 3 1 4 8 
2. 41 – 50 20 4 24 48 
3. 51 - 60 11 8 19 38 
4.  61 – 70 1 2 3 6 
 
Table 9 
S. 
No 
Post 
bronchodilator 
FEV1% 
Predominant 
bronchitis 
Predominant 
emphysema 
Total Percentage
1. Mild  (> 80%) 1 2 3 6 
2. 
Moderate 
(50 – 80 %) 
16 8 24 48 
3. 
Severe 
(30 – 50 %) 
14 3 17 34 
4. 
Very severe 
(< 30) or 
(< 50% with 
respiratory 
failure) 
4 2 6 12 
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FVC (Forced vital capacity)  
Maximal volume of air that can be exhaled during a forced manoeuvre  
FEV1 
Volume of air expired in the first second of maximal expiration after a 
maximal inspiration. 
 This is a measure of how quickly the lungs can be emptied. 
FEV1 / FVC % 
FEV1 expressed as a percentage of FVC gives a clinically useful index 
of air flow limitation when it is less than 70 %.  
In this study most of the cases had FEV1 / FVC % in the range between 
40 to 60% and most of them had moderate to severe COPD. 
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CHEST X-RAY FINDINGS 
Table 10 
S. 
No 
CXR findings Predominant 
bronchitis 
Predominant 
emphysema 
Total Percentage 
1. Emphysematous changes 4 12 16 32 
2. Increased broncho vascular markings 24 3 27 54 
3. Cardiomegaly 4 2 6 12 
4. Evidence of pulmonary hypertension 
 
6 
 
- 
 
6 
 
12 
 
 More than half of them had increased broncho vascular markings. 
Evidence of pulmonary hypertension was found in six patients. 
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ARTERIAL BLOOD GAS ANALYSIS 
Measurement of PaO2 
Table 11 
S.No PaO2 
(mmhg) 
Predominant 
bronchitis 
Predominant 
emphysema 
Total Percentage 
1. 50 - 60 9 4 13 26 
2. 40 – 49 6 1 7 14 
3. < 40 2 - 2 4 
 
Measurement of PCO2 
Table 12 
S. No PCO2 
(mmhg) 
Predominant 
bronchitis 
Predominant 
emphysema 
Total Percentage 
1. 41 - 50 5 3 8 16 
2. 51 – 60 3 - 3 6 
3. > 60 2 - 2 4 
 
 22 patients had evidence of hypoxemia and thirteen patients had 
hypercapnia. 
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ELECTRO CARDIOGRAPHIC FINDINGS 
Table 13 
S. 
No 
ECG changes Predominant 
bronchitis 
Predominant 
emphysema 
Total Percentage 
1. P Pulmonale 6 2 8 16 
2. Right axis deviation 10 3 13 26 
3. Left axis deviation 1 - 1 2 
4. RBBB - 2 2 4 
5. Low voltage QRS 1 4 5 10 
6. Lead I sign 2 - 2 4 
7. R/S ratio in V6 < 1 8 4 12 24 
8. R/S ratio in V1 > 1 5 1 6 12 
9 ST depression in L II, 
III, AVF 
4 3 7 14 
10. T Wave Inversion in 
V1 – V3 
4 2 6 12 
11. S I, S II, S III 1 - 1 2 
12. Ventricular ectopics  1 1 2 4 
13. Multifocal atrial 
tachycardia 
1 - 1 2 
 
In my study of 50 patients with COPD, the following 
electrocardiographic findings were observed: 
Right axis deviation   - 13 cases 
R/S ratio < 1 in V6   - 12 cases 
 “P” pulmonale   - 8 cases 
ST depression in II, III, aVF - 7 cases 
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T wave inversion in V1 – V3 - 6 cases 
Low voltage QRS   - 5 cases 
Right bundle branch block  - 2 cases 
Lead I sign    - 2 cases 
Ventricular ectopics   - 2 cases 
SI, SII, SIII pattern   - 1 case 
Multifocal atrial tachycardia -  1 case 
ECG evidence of right ventricular hypertrophy was found in 28 cases. 
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MEASUREMENT OF PULMONARY ARTERY PRESSURE BY ECHO-
DOPPLER 
Table 14 
S. No 
Systolic pulmonary 
artery pressure 
(mmhg) 
Predominant 
bronchitis 
Predominant 
emphysema Total Percentage 
1. 31 – 40 8 2 10 20 
2. 41 – 50 6 1 7 14 
3. 51 – 60 2 - 2 4 
4. 61 – 70 1 - 1 2 
5. 71 – 80 1 - 1 2 
 
21 patients had evidence of elevated pulmonary artery pressure by echo 
doppler and most of them had systolic pulmonary artery pressure in the range 
between 30 to 50 mmHg. 
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DISCUSSION 
AGE DISTRIBUTION 
I used the lower age of thirty years to calculate my estimate because this 
was the most frequently available cut off age in the reported studies. Moreover 
the disease is very rare below this age.  
It is found that obstructive air way disease is more common in the middle 
and old age. This is because  
- The risk of COPD increases with increasing age because it is related to 
smoking pack years and aging per se has a cumulative effect of exposure 
to environmental stress. 
- Mostly, the patients tend to ignore the initial symptoms and with 
increasing age, the symptoms worsen and they report to the hospital 
only at this juncture.  
- With improving medical care, the life expectancy tends to increase and 
with it the problem of COPD will also increase with advancing age. 
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SEX DISTRIBUTION 
In my study, the male is to female ratio is 2.12: 1 
Sex distribution of COPD in adults (> 30 years of age) in different parts 
of the country is generally similar.  
The following is the male female ratio in the Indian studies: 
Table 15: Male female ratio in Indian studies 
Authors Year Population M : F 
Wig et al 1964 Rural Delhi 1.32 : 1 
Viswanathan 1966 Patna 1.59 : 1 
Sikand et al 1966 Delhi 1.63 : 1 
Bhattacharya et al 1975 Rural UP 1.49 : 1 
Viswanathan & Singh 1977 Delhi – Rural 
 Urban 
1.34 : 1 
1.86 : 1 
Thiruvengadam et al 1977 Madras 1.58 :1 
Charan 1977 Rural Punjab 1.40 : 1 
Radha et al 1977 New Delhi 1.76 : 1 
Malik 1986 Chandigarh – Rural 
  Urban 
1.92 : 1 
2.31 : 1 
Jinda 1993 Chandigarh 2.60 : 1 
Ray et al 1995 Madras area 1.60 : 1 
 
The prevalence was uniformly higher among male in all reported 
studies. The male : female ratio vary from 1.32 : 1 to 2.60 : 1 with the median 
ratio at 1.60 : 1. 
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From the two south Indian studies which were carried out mainly in 
Madras region at different times, (1977 and 1995) the male female ratio was 
fairly constant maintaining at around 1.6: 1 which is that of the national 
average. 
The male female ratio tends to be much higher in case of urban 
population. Of several possible reasons which might account for a higher 
prevalence among males, the most important is the habit of smoking of 
tobacco.  
SMOKING PATTERN  
The reported smoker: non-smoker prevalence ratio ranged from 61.6 to 
91.1 % in ten different population studies. The median value was around 
82.3%.  
In my study, the ratio is about 66% of smokers, the majority of non – 
smokers in my study were female population. The greater the pack years, the 
greater the prevalence of COPD. 
Tobacco was introduced in India by the Portugese 400 years ago. Since 
then, tobacco consumption continued to rise in India. It has been estimated that 
there are 1.1 billion smokers worldwide and 182 million (16.6 %) of them live 
in India. 
It has been predicted by WHO that more than 500 million people alive 
today will be killed by tobacco by 2030. Tobacco is used for smoking as well 
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as in smokeless forms in India. Among the tobacco smokers, beedi smokers 
constitute 40%, cigarette smokers 20% and those using smokeless forms 40%.  
The prevalence of tobacco use during 1993 to 1994 was 23.2% in male 
(any age) and 4% in female in urban areas, 33.6 % in male and 8.8 % in female 
in rural areas. 
Smokers suffer an irreversible FEV1 loss of 4.4 to 10.4 ml per pack year 
smoked. Cigarette smoking also retards the normal increase in expiratory flow 
that occurs during growth in childhood or adolescence. The duration and 
intensity are of equal importance in determining these effects.  
Smoking cessation is associated with a small improvement in lung 
function, decrease in coughing and sputum expectoration and normalization of 
the rate of annual decline in lung function. 
PULMONARY FUNCTION TEST 
The primary problem in obstructive lung disease is an increased airway 
resistance. For each measurement of pulmonary function there is a normal 
value and range of normal limits. A common method of comparison is to 
compute a percentage of predicted normal values according to the equation.  
% predicted is equal to:  
Measured value 
         x 100 
Predicted normal value 
 44
Predicted values 
Predicted values vary as per age, sex, height and ethnic groups, are 
obtained by large scale studies in the community and are readily available for 
use. Values above 80 % of predicted are generally considered as normal. For 
patients with deformity of the thoracic cage such as Kyphoscoliosis, the arm 
span from finger tip to finger tip can be used as an estimate of height. 
Caucasians have the largest FEV1 and FVC and of the various ethnic 
groups, Polynesians are among the lowest. There is little difference in PEF 
between ethnic groups. The values for black Africans are 10 to 15 % lower 
than the Caucasians of similar age, sex and height because for a given standing 
height, their thorax is shorter. The Chinese have been found to have an FVC 
about 20 % lower and Indians about 10 % lower than matched Caucasians. 
Approximate conversion factors for adjusting European reference values 
of FVC and FEV1 for Indians are 0.9 for North Indians and 0.87 for south 
Indians.  
SPIROMETRY AND COPD 
- Spirometry is needed to make a firm diagnosis of COPD. 
- Together with the presence of symptoms, spirometry helps in staging 
COPD severity and can be a guide to specific treatment steps. 
- The lower the % predicted FEV1 the worse the subsequent 
prognosis. 
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- FEV1 declines over time and faster in COPD than in healthy 
subjects. 
- Spirometry can be used to monitor disease progression, buto to be 
reliable, the intervals between the measurements must be atleast 12 
months. 
Staging 
Once diagnosed, there are no widely accepted staging or severity scoring 
systems for patients with COPD. At present, we grade the disease based on a 
single objective physiologic measure such as FEV1. 
FEV1 as a % of its predicted value is the best single correlate of 
mortality in COPD. However, it is not until values fall to < 50% of predicted 
that mortality begins to increase. It follows that there is a need for a more 
comprehensive staging system that includes age, FEV1, ABG, body mass 
index, time walked distance, possible bio markers and genetic markers. 
CHEST X-RAY 
The main utility of the chest x-ray lies in excluding or suggesting 
alternate diagnoses that could cause a patient’s respiratory symptoms. 
In patients with severe emphysema, the chest x-ray may reveal bilateral 
lung hyperinflation with flattened diaphragms or the presence of bullae, 
characterized by thin arcuate lines circumscribing areas of radiolucency .It is 
important to bear in mind, how ever that a normal chest x-ray does not exclude 
the presence of emphysema. In one study, spirometry and HRCT were 
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performed on individuals with more than thirty pack years of smoking and 
normal chest x-rays .It was found that 58% of these individuals had evidence of 
significant emphysema. 
In chronic bronchitis, the principle abnormalities are bronchial wall 
thickening and an increase in lung markings which is sometimes termed “dirty 
chest”, refers to a general accentuation of linear markings throughout the lungs 
associated with loss of definition of vascular markings. Bronchial wall 
thickening may be manifested as ring shadows end on or as tubular shadows en 
face (tram tracks). 
The chest x-ray may also reveal radiographic changes of pulmonary 
hypertension in COPD .Patients can have right main pulmonary artery >16 mm 
in diameter and left main pulmonary prominence below aortic knuckle with 
pruning or poorly visualized peripheral vasculature .In lateral view right 
ventricular encroachment into the retrosternal air space can be seen . 
ARTERIAL BLOOD GAS ANALYSIS  
In my study, hypoxemia was found in 22 patients and hypercapnia. The 
hypercapnia was found only in patients having severe or very severe COPD. 
Arterial blood gases are commonly abnormal; as a rule, the more the 
severe the disease, the frequent the hypoxemia and hypercapnia. Arterial 
hypoxemia is the result of alveolar hypoventilation and ventilation – perfusion 
mismatching. 
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In COPD of mild to moderate severity, hypoxemia exits without 
hypercapnia. Although the V/Q inequality impairs both the uptake of oxygen 
and elimination of carbon dioxide , the tendency for elevation of PaCO2 is 
overcome by an increase in alveolar ventilation to well perfused units 
.However ,the increase in ventilation cannot correct the hypoxemia because of 
the nonlinear shape of the oxygen dissociation curve . 
An increase in arterial PaCO2  does not generally occur until FEV1 is 
less than approximately 1.2 litres, and the pressure of hypercapnia in a patient 
with FEV1 > 1.5 litres should raise the possibility of central hypoventilation or 
obstructive sleep apnea. 
Patients with COPD may experience episodic arterial desaturation 
during sleep, being more severe in patients categorized as blue bloaters than 
pink puffers. The desaturation is more during the REM sleep, that is partly due 
to the phasic inhibition of intercostal inspiratory muscle tone that is 
characteristic of REM sleep. 
Approximately 20% of patients with COPD and normal awake arterial 
Oxygen tension have nocturnal, nonapneic oxygen desatuation. Exertional 
oxygen desaturation is also common. These episodes are ameliorated with 
supplemental oxygen. 
Consequently, exercise and sleep oximetry should be completed in all 
patients with pulmonary hypertension. A formal overnight polysomnogram is 
indicated if the clinical presentation suggests sleep apnea.  
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In a recent prospective study of 43 patients with pulmonary arterial 
hypertension, with normal resting oxygenation, it was found that 70% had 
evidence of nocturnal hypoxemia.  
ELECTRO CARDIOGRAPHIC FINDINGS 
The ECG signs satisfying the right ventricular hypertrophy (RVH) 
criteria was found in 28 cases. 
Diagnostic criteria for RVH for persons older than 30 years of age 
- Right axis deviation > + 110o  
- Tall R wave in V1 > or = 7 mm, S wave in V1 < or = 2 mm 
- R/S ratio in V1 > 1, R/S ratio in V5  or V6 or = 1 
- S wave V5  or V6  > 2 mm 
- qR pattern in V1 ( increases specificity)  
- Most important is scrutiny for right atrial enlargement, peaked P 
waves with an amplitude in V1,  V2 or V3  > 1.5 mm or > 2.5 mm in 
II, III, aVF. 
- More than or equal to two criteria are required for the diagnosis of 
RVH. 
In an analysis of the contribution of individual signs in defining the long 
term prognosis of COPD patients, it was found that P wave axis of more than 
or equal to + 90o   (a sign of severe right atrial over load ) and the SI, SII, SIII 
pattern are independent negative prognostic predictors for survival. In the 
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patients presenting with one or both of these signs, had a three year survival 
rate of 44 and 14 % respectively versus 50 and 61% for patients having other or 
no use ECG signs of chronic corpulmonale. The remaining signs of chronic 
corpulmonale like RBBB, low voltage QRS, SIQ3 pattern were less 
consistently associated with poor survival. 
A P wave axis > or = 700 qualifies as the ECG hallmark of, and thus a 
screening criterion for COPD. A P wave axis more than or equal to 900     
probably identifies the stage of lung hyperinflation corresponding to very 
severe or almost terminal illness. In the two studies assessing this sign, its 
prevalence was known to be 24 % and 15% respectively. 
Although highly specific, ECG is generally insensitive in detecting 
pulmonary arterial hypertension (PAH). Kilcoyn et al evaluated the ECG of 
200 patients with COPD and Corpulmonale and noted at least one of the 
following changes: 
A rightward shift of the mean QRS axis 30 degrees or more from its 
previous position 
- Inverted biphasic or flattened T waves in precordial leads 
- ST depression in II, III, AVF  
- Right bundle branch block (RBBB) 
Incalzi et al reported that an SI, SII, SIII pattern, right atrial overload 
and alveolar – arterial oxygen gradient more than 48 mmhg during oxygen 
therapy were the strongest predictors of death. 
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SI, SII, SIII  pattern is a relatively uncommon finding not highly specific 
for COPD. It reflects an abnormal wave front rightward and superiorly oriented 
and opposed to the electrical forms of ventricular free wall. Low voltage QRS 
is frequently associated with chronic corpulmonale from COPD, but not 
associated with corpulmonale from other pulmonary diseases.  
Kok – Jensen studied the ECG of 228 patients between 40 to 69 years of 
age with COPD. According to him, the survival was very poor in the groups of 
patients with an ECG showing a QRS axis + 900 to 1800   and a PII amplitude of 
0.20 mv or more. Only 37% and 42% of the patients with these changes were 
alive after four years. Patients with changes only in standard leads had a 
significantly better survival than those with changes in precordial leads as well.  
ECHOCARDIOGRAPHIC FINDINGS 
In my study, 21 patients out of 28 who had evidence of right ventricular 
hypertrophy had elevated pulmonary artery pressure by Doppler 
echocardiography (> 30 mmhg systolic or > 20 mmhg mean pulmonary artery 
pressure). 
Echocardiographic screening for pulmonary hypertension is based on 
identification of the tricuspid regurgitant jet (TR), absent in normal individuals. 
Measurements of TR velocity (m / sec) provides an estimate of the back flow 
between the right ventricle and the right atrium. The systolic pulmonary artery 
pressure is estimated by the modified Bernoulli equation which is: 
P = 4 V2  
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where V is the velocity of the tricuspid regurgitant jet. By adding this pressure 
gradient to an estimate of the right atrial pressure, the right ventricle peak 
systolic pressure is determined. The right ventricle peak systolic pressure 
approximates pulmonary artery systolic pressure (PSAP) obtained by right 
heart catheterization.  
Numerous studies have examined the correlation between right 
ventricular systolic pressure (RVSP) as estimated by Doppler 
echocardiography and RVSP as directly measured during right heart 
catheterization, and most of the studies reported a relatively tight correlation 
(the r value ranged from 0.57 – 0.95). In a study by Hinderliter and colleagues, 
systolic pulmonary artery pressure was underestimated by atleast 20 mmhg in 
31% of patients. Other studies have demonstrated that the concordance 
between Doppler echocardiography and direct measurement via right heart 
catheterization worsens as the pressure rises, with poorer correlation when the 
systolic pulmonary arterial pressure is over 100mmhg. 
P Sahoo and Misra et al observed that in their ECG and 
echocardiographic evaluation of 50 cases, ECG abnormalities were found in 24 
cases. Out  of these, 20 cases had echocardiographic evidence of raised 
pulmonary artery pressure. 
In addition, 2 dimensional echocardiography can be used to assess RV 
dimensions and wall thickness. Pulmonary artery hypertension can also be 
assessed with pulsed Doppler echocardiography from the sub – xiphoid region 
using a general purpose ultrasound device. 
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CONCLUSION 
In my study of 50 cases of COPD, the conclusions are the following: 
- COPD is commonly seen in persons above 40 years of age ie., in the 
middle and old aged people. 
- It is more common among males. 
- It is associated with the smoking pattern of more than 20 pack years. Its 
severity increases with increasing age and duration of smoking. 
- ECG abnormalities suggestive of pulmonary hypertension (Right 
ventricular hypertrophy) was found in more than half of these cases. 
Poor progression with R/S is < 1 was found in 12 cases, right ventricular 
strain patterns like ST depression in II, III AVF and T wave inversion 
was found in 7 and 6 cases respectively, low voltage QRS in 5 cases. 
Other rare ECG abnormalities like lead I sign and SI, S II, S III was 
found in 2 and 1 cases respectively. Rhythm abnormalities like 
ventricular ectopics, RBBB are found in 2 cases and multi focal atrial 
tachycardia in 1 case.  
- The presence of raised pulmonary artery pressure was confirmed using 
the Doppler Echo in 75 % of the patients showing ECG evidence of 
right ventricular hypertrophy. 
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SUMMARY 
COPD is a major and increasing health problem which is predicted to 
become the third commonest cause of death and fifth commonest cause of 
disability in the world by the year 2020. Despite its enormous global 
importance, there has been relatively little     research into COPD and it is the 
most under-funded disease in relation to the global burden of diseases.  
This study was carried out to see the ECG and Echocardiographic signs 
in COPD. It was conducted in 50 cases of COPD diagnosed clinically and 
confirmed by Spirometry. It is an observational study and the relevant 
information was obtained in a predesigned proforma using interview technique. 
All the necessary investigations was done and ECG was done in all cases. 2 D 
and Doppler Echocardiography was done in cases showing ECG evidence of 
right ventricular hypertrophy (RVH). The results were carefully documented. 
ECG evidence of RVH was found in 28 cases, out of which 21 cases was 
confirmed using echocardiography. Thus, raised pulmonary artery pressure was 
found in 75 % of cases showing ECG evidence of Right Ventricular 
Hypertrophy. 
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S NO. NAME AGE / SEX FVC FEV1 
FEV1/ 
FVC % 
QRS 
AXIS 
P 
PULM 
R/S IN 
V1 
R/S IN 
V6 
RBBB RV STRAIN 
PAP 
(mmhg) OTHERS 
1 Adam mohammed 48 / M 1.8 0.7 44 +90  <1 <1   36  
2 Noor jehan 48/ F 2.1 1.2 57 +80  <1 >1     
3 Daisy Solomon 50/F 1.8 1.0 55 +70  <1 =1     
4 Krishnaiah 35 / M 2.0 1.3 68 +70  <1 >1    Sinus tachycardia 
5 Malarkodi 50/F 1.7 0.8 77 +110  =1 <1   34 Low volatage QRS 
6 Dhanalakshmi 52/F 1.9 0.9 47 +120 + >1 >1 +  38 SI, SII, SIII 
7 Chakravarthi 45/M 2.1 1.2 27 +80  <1 >1     
8 Sundar 43/M 1.8 1.0 56 +70  <1 >1     
9 Gopalakrishnan 58/M 1.9 1.0 53 +110  =1 >1   36  
10 Govindan 50/M 2.4 1.1 48 +90  <1 <1     
11 Jayanthy 56/F 2.1 1.2 57 +70  <1 >1  + 40  
12 Mariamma 40/F 1.8 0.9 50 +80  <1 >1     
13 Shankar 37/M 2.3 1.9 61 +90  <1 >1  +  Lead 1 sign 
14 navaneethan 57/M 2.2 1.1 50 +70  <1 >1    Ventricular ectopics 
15 Kandaswamy 64/M 2.1 1.0 47 +90  <1 <1   38  
16 Sankarnarayan 57/M 2.1 1.2 57 -60  <1 >1     
17 Kannammal 75/F 1.4 0.5 36 +140 + >1 <1  + 64 Low voltage 
S NO. NAME AGE / SEX FVC FEV1 
FEV1/ 
FVC % 
QRS 
AXIS 
P 
PULM 
R/S IN 
V1 
R/S IN 
V6 
RBBB RV STRAIN 
PAP 
(mmhg) OTHERS 
QRS 
18 Kuppammal 40/F 3.1 2.1 67 +70  <1 >1    Sinus tachycardia 
19 Agis Khan 45/M 1.4 0.8 57 +80  <1 >1     
20 Unnamalai 62/F 1.8 0.7 44 +120 + >1 >1   72  
21 Vasantharaj 42/M 2.3 1.3 56 +80  <1 >1     
22 Jothi 56/M 1.8 1.0 55 +70  <1 >1     
23 Chandran 53/M 2.1 1.2 57 +80  <1 >1    Low voltage QRS 
24 Ethiraj 53/M 2.0 1.0 50 +70  <1 >1     
25 Rosamma 55/F 1.8 0.9 50 +90  <1 >1   40  
26 Mahalingam 59/M 1.8 1.0 56 +70  <1 >1  + 42  
27 Kannammal 50/F 1.8 1.0 55 +80  <1 <1     
28 Ramadas 60/M 2.2 1.0 49 +90  <1 >1    Lead 1 sign 
29 Arumugam 40/M 1.7 1.0 59 +90  <1 >1    Ventricular ectopics 
30 Perumal 55/M 1.8 0.9 50 +70  <1 =1   42  
31 Jayaraman 59/M 2.1 0.9 46 +90  <1 >1     
32 Pachaiammal 40/F 1.8 0.9 50 +90  <1 >1     
33 Raja 42/M 1.7 0.7 41 +120 + >1 <1   48  
34 Radhakrishnan 56/M 1.8 1.0 56 +70  <1 >1     
35 Ponnusamy 52/M 1.9 0.8 50 +80  <1 =1     
S NO. NAME AGE / SEX FVC FEV1 
FEV1/ 
FVC % 
QRS 
AXIS 
P 
PULM 
R/S IN 
V1 
R/S IN 
V6 
RBBB RV STRAIN 
PAP 
(mmhg) OTHERS 
36 Lalitha 45/F 2.4 1.1 48 +110 + =1 <1   48  
37 Ranjitham 55/F 1.9 1.0 52 +70  <1 >1    
Multifocal 
atrial 
Tachycardia 
38 Padmavathy 56/F 1.6 0.7 45 +110  =1 >1   46  
39 Kanikannan 82/M 1.6 0.6 37 +110  <1 <1   50  
40 Selvaraj 68/M 1.7 0.7 38 +120 + >1 >1  + 44 Sinus tachycardia 
41 Manickam 60/M 1.8 1.0 55 +90  <1 >1     
42 Sethuraman 75/M 1.7 0.7 41 +120  >1 >1 +  54  
43 Manoharan 60/M 1.9 1.0 52 +90  <1 <1     
44 Subramani 60/M 1.8 1.0 55 -30  <1 =1     
45 Venkatesan 60/M 1.8 0.9 50 +70  <1 >1    Low voltage QRS 
46 Stalin Rehman 62/M 1.5 0.6 40 +110 + =1 >1   56  
47 Satyanarayanan 64/M 1.8 0.7 44 +100  <1 <1   34 Low voltage QRS 
48 Abdul khuda 61/M 1.9 0.9 48 +100  <1 <1   56  
49 Kanakamma 55/F 1.7 0.7 41 +120 + >1 >1  + 38  
50 Ashok 58/M 1.8 0.9 50 +80  <1 >1     
 
  
 
 
 
 
 
 
 
 
 
Fig 1. SPIROMETER 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.  PATIENT PERFORMING SPIROMETRY 
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Fig 3. SPIROMETRY REPORT  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.EMPHYSEMA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.CHRONIC BRONCHITIS SHOWING PROMINENT BRONCHO 
VASCULAR MARKINGS  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.CHEST X-RAY SHOWING PULMONARY ARTERIAL 
ENLARGEMENT 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7.ECG SHOWING LOW VOLTAGE QRS  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 8.  ECG SHOWING LEAD I SIGN  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 9.ECG SHOWING P PULMONALE 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 10. ECG SHOWING RVH 
  
 
 
 
 
 
 
 
 
 
Fig 11.ECG SHOWING RBBB 
 
 
 
 
 
 
 
 
 
Fig 12.ECG SHOWING MULTIFOCAL ATRIAL TACHYCARDIA 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 13. DOPPLER ECHO SHOWING REGURGITANT JET WITH 
DILATED  RA AND RV 
